Firebrick Pharma Limited (ASX:FRE)

Australia flag Australia · Delayed Price · Currency is AUD
0.0520
0.00 (0.00%)
At close: Dec 12, 2025
-5.45%
Market Cap13.02M
Revenue (ttm)515.51K
Net Income (ttm)-2.63M
Shares Out250.37M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,335
Average Volume142,176
Open0.0530
Previous Close0.0520
Day's Range0.0520 - 0.0530
52-Week Range0.0510 - 0.1000
Beta1.35
RSI31.72
Earnings DateDec 4, 2025

About Firebrick Pharma

Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia. [Read more]

Sector Healthcare
Founded 2012
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol FRE
Full Company Profile

Financial Performance

In 2025, Firebrick Pharma's revenue was 515,507, a decrease of -81.26% compared to the previous year's 2.75 million. Losses were -2.63 million, 124.0% more than in 2024.

Financial Statements

News

There is no news available yet.